
In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.
In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.
Study finds some patients may be able to go up to 9 months between care visits without an impact on viral load, while other patients need to maintain the current recommended rate of
An economic evaluation finds that a bundled approach of stronger hand hygiene and improved environmental cleaning proved to be the best combination for reducing C. diff.
The results of a new study show that patients who are co-infected with the hepatitis C virus (HCV) and HIV can experience cure rates similar to individuals infected with HCV alone when both groups receive direct-acting antiviral drugs.
A new study reveals that direct-acting antivirals, like sofosbuvir, may help improve kidney function in some patients.
A new study finds that sofosbuvir-based treatment in a real-life setting offered SVR rates greater than 90% in hard-to-treat HCV genotype 3 patients with advanced liver disease.
Study finds that hepatitis C patients who had reached sustained virologic response using direct-acting antiviral drugs show a considerably reduced risk of the most common type of liver cancer.
A naturally occurring compound in plums has been found to block the entry of the hepatitis C virus into cultured liver cells.
A recent report coming from the O’Neill Institute for National & Global Health Law takes a closer look at the tools needed to achieve hepatitis C elimination in the United States.
The lack of availability of generic DAAs in many other parts of the world increases prices and often limits treatment to people with later stages of the disease.
Researchers may have found a way to broaden the US kidney transplant supply list.
Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.
Published: March 4th 2017 | Updated:
Published: May 15th 2017 | Updated:
Published: May 26th 2017 | Updated:
Published: June 28th 2017 | Updated:
Published: July 14th 2017 | Updated:
Published: July 24th 2017 | Updated: